NPPA revises ceiling price of Metronidazole Injection 0.5%w/v
Advertisement
New Delhi:In accordance with price revision as per the annual wholesale price index (WPI) of 12.1218% increase, through a recent notification, the National Pharmaceuticals Pricing Authority (NPPA), the Ministry of Chemicals and Fertilisers, the Government of India, has revised and fixed the ceiling price of the metronidazole injection (0.5% w/v) under the Drug (Price Control) Order 2013.
The ceiling price of Metronidazole Injection Injection (0.5% w/v) and 500 mg per 100 mL in 100-mL packs for packages in nonglass containers in plastic bottles with euro heads having special features, manufactured by Otsuka Pharmaceutical, Denis Chem Lab, Rusoma Laboratories, and Sachin Parenteral, is fixed at Rs 0.24 per mL.
Scheduled formulation means any formulation, included in the First Schedule whether referred to by generic versions or brand names (mainly products covered under the National List of Essential Medicines are Scheduled Formulation). In other words, all medicines that are covered in the National List of Essential Medicine, which are notified in Schedule 1, by the Govt. are scheduled formulation.
"Ceiling Price" refers to a price fixed by the Government for Scheduled Formulations in accordance with the provisions of the drugs (prices control) order, 2013. The ceiling Price is the Maximum Price to Retailer (excluding Taxes, if any)for the given product.
The notice declared in exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 486(E) dated 02.02.2023 read with corrigendum, in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, has revised the price based on Wholesale price index(WPI) of 2022 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:
Sl No | Medicines | Dosage Form and Strength | Unit | Ceiling price (wef01.04.2023 with WPI @ 12.1218%) |
(1) | (2) | (3) | (4) | (5) |
1 | Metronidazole | Injection (0.5%w/v) /500mg/100ml in 100ml pack for packages in non- glass container in plastic bottle with euro head having special features | Per ml | 0.24 |
Sl. No. | Name of Manufacturer |
(1) | (2) |
1 | M/s Otsuka Pharmaceutical India Private Ltd. |
2 | M/s Denis Chem Lab Ltd. |
3 | M/s Rusoma Laboratories Pvt. Ltd. |
4 | M/s Sachin Parenteral Pvt. Ltd |
The notification further added,
(a) The ceiling prices are applicable with effect from 01.04.2023 (ceiling prices are inclusive of Wholesale Price Index (WPI) @12.1218% for the year 2022 over 2021).
(b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(c) The manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 486(E) dated 02.02.2023 read with corrigendum (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 12.1218% for years 2022 over 2021 in accordance with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.
(e) Any other manufacturer claiming a separate ceiling price for Metronidazole Injection (0.5%w/v) /500mg/100ml in 100ml pack for packages in non-glass containers in a plastic bottle with a euro head having special features shall apply to NPPA for separate ceiling price approval.
(f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of the information under this subparagraph shall be construed as non-revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display a price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both, as specified in the above table, launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of a such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
(j) The manufacturers of above said scheduled formulations shall furnish quarterly returns to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of the discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
(l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.
Also Read: NPPA Revises Ceiling Price of 233 Scheduled Formulation, Details
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.